The early allergic response in small airways of human precision-cut lung slices.
To study the role of small airways in the early allergic response (EAR), the method of human precision-cut lung slices (PCLS) was developed and used to examine the bronchoconstriction elicited by passive sensitisation and allergen provocation. Viable human PCLS of 250-microm thickness containing airways <1.5 mm in outer diameter were prepared from lung lobes obtained from lung resection and taken into culture. According to the low release of lactate dehydrogenase and the constant ciliary beat frequency, human PCLS were viable for at least 3 days. Following overnight passive sensitisation with serum from allergic individuals, administration of grass-pollen extract or activating immunoglobulin E antibody resulted in immediate airway contraction that was quantified by videomicroscopy. The extent of the EAR increased with decreasing airway size (outer airway diameter), with the strongest response occurring in the terminal bronchioles. Histamine receptor antagonism was ineffective, and leukotriene or thromboxane receptor antagonism attenuated the early allergic response only in some cases. However, simultaneous blockade of leukotriene and thromboxane receptors almost completely prevented the early allergic response in the precision-cut lung slices from all individuals, suggesting such a dual treatment as a potential future asthma therapy.
Wohlsen
A
A
Research Centre Borstel, Borstel, Germany.
Martin
C
C
Vollmer
E
E
Branscheid
D
D
Magnussen
H
H
Becker
W M
WM
Lepp
U
U
Uhlig
S
S
D000085:Acetates / Q000494:pharmacology; D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic; D001980:Bronchi / Q000187:drug effects / Q000276:immunology* / Q000648:ultrastructure; D001985:Bronchial Provocation Tests; D016084:Bronchoconstriction / Q000187:drug effects / Q000276:immunology*; D002923:Cilia / Q000187:drug effects / Q000276:immunology / Q000648:ultrastructure; D046508:Culture Techniques / Q000379:methods*; D003521:Cyclopropanes; D005231:Fatty Acids, Unsaturated; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology; D006967:Hypersensitivity / Q000276:immunology*; D007116:Immunization, Passive; D008168:Lung / Q000187:drug effects / Q000276:immunology* / Q000648:ultrastructure; D011804:Quinolines / Q000494:pharmacology; D011930:Reaction Time / Q000187:drug effects / Q000276:immunology; D013440:Sulfides; D013997:Time Factors; D014311:Triprolidine / Q000494:pharmacology
D000085:Acetates; D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003521:Cyclopropanes; D005231:Fatty Acids, Unsaturated; D006834:Hydrazines; D011804:Quinolines; D013440:Sulfides; D014311:Triprolidine; C045749:SQ 29548; C093875:montelukast